![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TTL |
Gene summary for TTL |
![]() |
Gene information | Species | Human | Gene symbol | TTL | Gene ID | 150465 |
Gene name | tubulin tyrosine ligase | |
Gene Alias | TTL | |
Cytomap | 2q14.1 | |
Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q8NG68 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
150465 | TTL | HCC1_Meng | Human | Liver | HCC | 2.30e-18 | 1.76e-02 | 0.0246 |
150465 | TTL | HCC2 | Human | Liver | HCC | 9.58e-20 | 3.89e+00 | 0.5341 |
150465 | TTL | Pt14.a | Human | Liver | HCC | 2.24e-03 | 2.59e-01 | 0.0169 |
150465 | TTL | S014 | Human | Liver | HCC | 1.02e-03 | 2.53e-01 | 0.2254 |
150465 | TTL | S016 | Human | Liver | HCC | 1.25e-02 | 1.97e-01 | 0.2243 |
150465 | TTL | S028 | Human | Liver | HCC | 1.53e-16 | 5.89e-01 | 0.2503 |
150465 | TTL | S029 | Human | Liver | HCC | 2.40e-10 | 5.72e-01 | 0.2581 |
150465 | TTL | C04 | Human | Oral cavity | OSCC | 1.01e-08 | 6.21e-01 | 0.2633 |
150465 | TTL | C21 | Human | Oral cavity | OSCC | 4.49e-08 | 3.48e-01 | 0.2678 |
150465 | TTL | C30 | Human | Oral cavity | OSCC | 6.89e-11 | 5.60e-01 | 0.3055 |
150465 | TTL | C38 | Human | Oral cavity | OSCC | 8.98e-05 | 5.37e-01 | 0.172 |
150465 | TTL | C46 | Human | Oral cavity | OSCC | 2.38e-02 | 1.46e-01 | 0.1673 |
150465 | TTL | C51 | Human | Oral cavity | OSCC | 8.78e-04 | 2.58e-01 | 0.2674 |
150465 | TTL | C09 | Human | Oral cavity | OSCC | 3.48e-02 | 9.74e-02 | 0.1431 |
150465 | TTL | SYSMH1 | Human | Oral cavity | OSCC | 5.30e-08 | 2.88e-01 | 0.1127 |
150465 | TTL | SYSMH2 | Human | Oral cavity | OSCC | 3.78e-09 | 3.36e-01 | 0.2326 |
150465 | TTL | SYSMH3 | Human | Oral cavity | OSCC | 3.60e-23 | 5.98e-01 | 0.2442 |
150465 | TTL | male-WTA | Human | Thyroid | PTC | 2.21e-14 | 1.64e-01 | 0.1037 |
150465 | TTL | PTC01 | Human | Thyroid | PTC | 1.95e-02 | 3.73e-02 | 0.1899 |
150465 | TTL | PTC04 | Human | Thyroid | PTC | 1.89e-05 | 1.61e-01 | 0.1927 |
Page: 1 2 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00171485 | Oral cavity | OSCC | negative regulation of translation | 113/7305 | 245/18723 | 1.34e-02 | 4.45e-02 | 113 |
GO:00224086 | Oral cavity | OSCC | negative regulation of cell-cell adhesion | 92/7305 | 196/18723 | 1.41e-02 | 4.64e-02 | 92 |
GO:00488637 | Oral cavity | OSCC | stem cell differentiation | 96/7305 | 206/18723 | 1.55e-02 | 4.99e-02 | 96 |
GO:00800091 | Oral cavity | OSCC | mRNA methylation | 11/7305 | 16/18723 | 1.56e-02 | 4.99e-02 | 11 |
GO:0002181110 | Oral cavity | LP | cytoplasmic translation | 124/4623 | 148/18723 | 5.09e-52 | 3.19e-48 | 124 |
GO:0022613110 | Oral cavity | LP | ribonucleoprotein complex biogenesis | 259/4623 | 463/18723 | 7.20e-48 | 2.25e-44 | 259 |
GO:0008380110 | Oral cavity | LP | RNA splicing | 237/4623 | 434/18723 | 1.82e-41 | 3.79e-38 | 237 |
GO:0042254110 | Oral cavity | LP | ribosome biogenesis | 173/4623 | 299/18723 | 8.97e-35 | 1.41e-31 | 173 |
GO:0000375110 | Oral cavity | LP | RNA splicing, via transesterification reactions | 181/4623 | 324/18723 | 1.36e-33 | 1.70e-30 | 181 |
GO:0000377110 | Oral cavity | LP | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 179/4623 | 320/18723 | 2.48e-33 | 2.22e-30 | 179 |
GO:0000398110 | Oral cavity | LP | mRNA splicing, via spliceosome | 179/4623 | 320/18723 | 2.48e-33 | 2.22e-30 | 179 |
GO:000636418 | Oral cavity | LP | rRNA processing | 134/4623 | 225/18723 | 6.08e-29 | 4.23e-26 | 134 |
GO:001607218 | Oral cavity | LP | rRNA metabolic process | 136/4623 | 236/18723 | 2.37e-27 | 1.48e-24 | 136 |
GO:003447014 | Oral cavity | LP | ncRNA processing | 184/4623 | 395/18723 | 1.20e-21 | 3.12e-19 | 184 |
GO:000641319 | Oral cavity | LP | translational initiation | 75/4623 | 118/18723 | 3.96e-19 | 7.52e-17 | 75 |
GO:003466011 | Oral cavity | LP | ncRNA metabolic process | 205/4623 | 485/18723 | 6.46e-18 | 1.09e-15 | 205 |
GO:190331119 | Oral cavity | LP | regulation of mRNA metabolic process | 129/4623 | 288/18723 | 5.70e-14 | 6.10e-12 | 129 |
GO:0042274110 | Oral cavity | LP | ribosomal small subunit biogenesis | 48/4623 | 73/18723 | 1.42e-13 | 1.35e-11 | 48 |
GO:000644616 | Oral cavity | LP | regulation of translational initiation | 48/4623 | 79/18723 | 1.04e-11 | 7.66e-10 | 48 |
GO:003465518 | Oral cavity | LP | nucleobase-containing compound catabolic process | 161/4623 | 407/18723 | 1.61e-11 | 1.15e-09 | 161 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TTL | SNV | Missense_Mutation | c.971N>G | p.Glu324Gly | p.E324G | Q8NG68 | protein_coding | tolerated(0.16) | benign(0.026) | TCGA-B6-A0IC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TTL | SNV | Missense_Mutation | novel | c.131G>T | p.Arg44Met | p.R44M | Q8NG68 | protein_coding | deleterious(0) | probably_damaging(0.909) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TTL | SNV | Missense_Mutation | novel | c.968A>G | p.Glu323Gly | p.E323G | Q8NG68 | protein_coding | deleterious(0.04) | benign(0.093) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TTL | SNV | Missense_Mutation | rs746535633 | c.279N>T | p.Trp93Cys | p.W93C | Q8NG68 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-DG-A2KK-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
TTL | SNV | Missense_Mutation | c.217N>T | p.Arg73Cys | p.R73C | Q8NG68 | protein_coding | deleterious(0) | probably_damaging(0.965) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TTL | SNV | Missense_Mutation | c.414G>T | p.Lys138Asn | p.K138N | Q8NG68 | protein_coding | tolerated(0.13) | benign(0.163) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TTL | SNV | Missense_Mutation | novel | c.661N>A | p.Leu221Ile | p.L221I | Q8NG68 | protein_coding | deleterious(0.03) | possibly_damaging(0.883) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TTL | SNV | Missense_Mutation | c.170N>T | p.Gly57Val | p.G57V | Q8NG68 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TTL | SNV | Missense_Mutation | c.679C>A | p.Pro227Thr | p.P227T | Q8NG68 | protein_coding | deleterious(0.02) | possibly_damaging(0.575) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TTL | SNV | Missense_Mutation | rs780073175 | c.218N>A | p.Arg73His | p.R73H | Q8NG68 | protein_coding | deleterious(0.02) | probably_damaging(0.925) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |